Research. Advocacy. Support.

We advance ovarian cancer research while supporting women and their families.

Learn more about OCRFA

Register for OCRFA's Ovarian Cancer National Conference

Join us for an informative and transformative weekend of inspiration and hope, July 13-15 in Washington DC. Meet other survivors, patients and caregivers, hear from experts, and make lasting connections with others who have been touched by ovarian cancer.

Learn More and Register

Know Your Risks

About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.

Learn about your risks

Risk Factors

Many factors can increase or decrease a woman's risk of developing ovarian cancer.

Increases Risk

  • Family history of breast, ovarian or colon cancer
  • Genetic mutations like BRCA
  • Post-menopausal
  • Increased age

Decreases Risk

  • Pregnancy
  • Breastfeeding
  • Use of oral contraceptives

Know the Symptoms

  • Bloating
  • Difficulty Eating
  • Pelvic / Abdominal Pain
  • Urinary Frequency

If these symptoms occur for more than 2 weeks and these symptoms are new or unusual for you, see a gynecologist and ask about ovarian cancer. Research shows that seeing a gynecologic oncologist for surgery and treatment significantly improves outcomes.

Spring Advocacy Day

OCRFA and our amazing advocates brought #TealAction to Capitol Hill on March 6, highlighting the need for increased ovarian cancer research funding and support at the federal level. Together, we are the voice of the ovarian cancer community.

Learn More About OCRFA Advocacy

Latest News

  • Study Shows Survival Advantage of Primary Cytoreductive Surgery

    (April 26, 2018) The International Journal of Gynecological Cancer recently featured a retrospective study on the treatment patterns of women with advanced high-grade serous ovarian carcinoma (HGSC). Of the 852 women with HGSC included in the study, 53% of them underwent primary cytoreductive surgery (PCS), or surgery before chemotherapy to remove as much as the tumor… More

    Posted
  • OCRFA Funded Study Explores Implant that Detects Ovarian Cancer Biomarker

    (April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice. HE4, like CA-125, is approved by the U.S. Food and Drug Administration as a biomarker for HGSC. However, these biomarkers are more… More

    Posted
  • Register for OCRFA’s Ovarian Cancer National Conference on July 13-15 in Washington, DC

    Join ovarian cancer survivors, caregivers, researchers and healthcare providers at OCRFA’s Ovarian Cancer National Conference – an informative and transformative weekend of hope, inspiration and fun. Get a front row seat at expert plenary and breakout sessions, from the newly-expanded Ask the Experts, to sessions on understanding PARP inhibitors, and sexual health after cancer. Learn… More

    Posted

Upcoming Events